Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of High-Dose Omalizumab in Mild to Moderate Asthma
NCT00546143Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Aug 2008
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Novartis. Started Jul 2007; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00546143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546143.